Sitemap Page
Posts by category
- Category: Medications
- Category: Pharmaceuticals
- Category: Pharmos News Releases
- Viagra Generic Coupon at My Canadian Pharmacy
- My Canadian Pharmacy: Special Programs to Save Time & Money
- Pharmos Corporation Reports 2011 Second Quarter Results
- Pharmos Corporation Reports First Quarter 2011 Results
- Pharmos Corporation Reports Fourth Quarter and Full Year 2010 Results
- Pharmos Corporation Reports 2010 Third Quarter Results
- Pharmos Corporation Reports 2010 Second Quarter Results
- Pharmos Corporation Reports First Quarter 2010 Results
- Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
- Pharmos Corporation Reports 2009 Third Quarter Results
- Pharmos Corporation Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam
- Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study
- Pharmos Corporation Reports 2009 Second Quarter Results
- Pharmos Corporation Reports 2009 First Quarter Results
- Pharmos Completes Private Placement – Raises $1.8 Million
- Pharmos Issues Business Update on Dextofisopam Trial and Financing
- Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination Company Also Receives Going Concern Audit Opinion
- Pharmos Corporation Announces Modification to Dextofisopam Trial Size Objectives Can Still Be Achieved
- Pharmos Corporation Reports 2008 Fourth Quarter Results
- Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists
- Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
- Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
- Pharmos Corporation Reports 2008 Third Quarter Results
- Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
- Pharmos Corporation announces that it will cease operations in Israel
- Pharmos Corporation Reports 2008 Second Quarter Results
- Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
- Pharmos Corporation Reports 2008 First Quarter Results
- Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
- Pharmos Corporation Announces Board and Management Changes Robert F. Johnston Named Executive Chairman of the Board S. Colin Neill Named President
- Pharmos Corporation Completes Initial Closing of Private Placement
- Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
- Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
- Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
- Pharmos Corporation Reports 2007 Third Quarter Results
- Pharmos Restructures Operations in Israel
- Pharmos Receives Notice Related to Nasdaq Minimum Bid Price Rule
- Pharmos Issues Letter to Shareholders
- Pharmos Corporation Reports 2007 Second Quarter Results Restructuring and Cost Reduction Plan Implemented in Early August 2007
- Pharmos Commences Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
- Pharmos Commences Phase 2b Irritable Bowel Syndrome Study
- Pharmos Corporation Announces Settlement of Class Action Litigation
- Pharmos Corporation Reports 2007 First Quarter Results
- Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
- Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Nociceptive Pain in Third Molar Dental Extraction Model
- Pharmos Receives $1.5 Million Grant
- Pharmos Corporation Reports 2006 Year-end and Fourth Quarter Results
- Pharmos Announces Appointment of Elkan Gamzu as New Chief Executive Officer
- Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
- Pharmos Completes Preclinical Toxicology and Safety Pharmacology Studies in Oral Cannabinor
- Pharmos Corporation to Present at the 2006 RBC Capital Markets Healthcare Conference
- SCHEDULE CHANGE: Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference at 10:30 AM Eastern Time on December 7, 2006
- Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference
- Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream
- Pharmos Corporation Reports 2006 Third Quarter Results
- Pharmos Corporation to Present at the C.E. Unterberg Towbin Life Sciences Conference
- Pharmos Shareholders Approve Vela Pharmaceuticals Transaction
- Pharmos Appoints S. Colin Neill as CFO
- Pharmos and Vela Revise Transaction Terms
- Pharmos Corporation Reports 2006 Second Quarter Results
- Pharmos Commences Dosing in Second Phase 2a Study of Cannabinor in Experimentally Induced Pain
- Pharmos Expands Corporate Website and Adds Hebrew Language Site Authorities
- Pharmos Commences Patient Dosing in Phase 2a Cannabinor Nociceptive Pain Study
- Pharmos Phase 2a Cannabinor Study to Evaluate Analgesic Activity and Safety in Acute Pain Approved by UK Regulatory Authorities
- Pharmos Corporation Engages Burrill & Company for Business Development Initiatives
- Pharmos Corporation to Present at the Rodman & Renshaw Third Annual Global Healthcare Conference
- Pharmos Corporation Reports 2006 First Quarter Results
- Pharmos Receives Grant from Israel Government
- Pharmos Sets Strategic Priorities for Development of Vela Compounds
- U.S. Congressman Mike Ferguson (R-NJ) Will Tour Pharmos Facility
- Pharmos Agrees to Acquire Vela Pharmaceuticals Inc.
- Pharmos Corporation Reports 2005 Fourth Quarter and Year-end Results
- Pharmos Completes Phase I Cannabinor Study
- Senior Pharmaceutical Executive Joins Pharmos Management
- Pharmos Corporation Reports 2005 Third Quarter Results
- Pharmos Corporation to Present at the 7th Annual Rodman & Renshaw Techvest Healthcare Conference
- Pharmos to Present at the 2005 BIO Investor Forum
- Pharmos Announces Shareholder Approval of All Proxy Proposals at Regularly Scheduled Annual General Meeting
- Pharmos Initiates Phase I Trial of CB2-Selective Drug Candidate Cannabinor
- Pharmos Corporation Reports 2005 Second Quarter Results
- Pharmos to Initiate Clinical Program in Tissue-directed Treatment of Inflammation and Pain
- Dr. Abraham Sartani Appointed to Pharmos Board
- Pharmos to Present at the BIO 2005 Business Forum
- Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum at The Princeton Club of New York on Tuesday, June 15, 2005, 2:35 pm ET
- Pharmos Announces Reverse Split of Common Stock
- Pharmos Corporation to Present at the Bio-Tech Israel 2005 Conference
- Pharmos Receives Grant from Israel Government
- Pharmos Corporation Reports 2005 First Quarter Results
- Pharmos Corporation Strengthens Management Team to Support Pipeline Development
- Pharmos Corporation Reports 2004 Results
- Pharmos Announces Conference Call for Q4 and FY2004 Financial Results and Comments on Pipeline Status
- Pharmos Receives Milestone Payment From Bausch & Lomb for Zylet™ Commercial Launch
Pages
- About Our Company
- Asterias Biotherapeutics Inc. (AST): Our New Investor
- Business Development
- CB2-Selective Program: Cannabinor
- CB2-Selective Program: Second-Generation Compounds
- Corporate Governance
- Corporate Presentation
- Development Plan
- Dextofisopam for IBS
- Email, Address, Phone: Company Contacts
- Fact Sheet
- How to Track Your Order
- Legal Disclaimer
- Managment Board
- News Room
- Newswire and Healthcare Information
- Our Investors
- Pharmos Corporation
- Sitemap Page